ADCs : antibodies and cytotoxic molecules united against tumours
Contexte historique des ADC L’histoire des immuno-conjugués appelés Antibody-Drug Conjugate ou ADC en anglais, ces biomédicaments révolutionnaires en oncologie, remonte aux travaux visionnaires de Paul Ehrlich, un scientifique allemand du début du 20ème siècle. Paul Ehrlich est souvent considéré comme le père de l’immunologie moderne et de la chimiothérapie. Son concept de « balle magique […]
antibody-drug conjugates
This month’s MabDesign market analysis gives you an overview of the antibody-drug conjugates market and projects in development.
Monoclonal antibodies: the stars of therapeutic proteins
Hybridoma technology for the production of monoclonal antibodies (mAbs), awarded the Nobel Prize for Medicine in 1984, revolutionized serotherapy, which previously used patient serum containing mixtures of antibodies. More targeted and therefore more effective, mAbs offer innovative perspectives in the treatment of various diseases, and have become an essential therapeutic strategy in our pharmaceutical arsenal.
